Prognostic Significance of GSTP1, XRCC1 and XRCC3 Polymorphisms in Non-small Cell Lung Cancer Patients
Prognostic Significance of GSTP1, XRCC1 and XRCC3 Polymorphisms in Non-small Cell Lung Cancer Patients
复制标题
DOI：
10.7314/apjcp.2012.13.9.4413
复制
发表时间：
2012-01-01
影响因子：
--
通讯作者：
Shen, Zhen-Ya
中科院分区：
文献类型：
--
作者：
Ke, Hong-Gang;Li, Jun;Shen, Zhen-Ya
目的：接受铂类化疗的非小细胞肺癌（NSCLC）患者化疗敏感性和临床结果的个体差异可能是由于遗传因素造成的。我们的研究旨在探讨 GSTP1、XRCC1 和 XRCC3 在接受化疗的 NSCLC 患者中的预后作用。方法：连续选取南通大学附属医院2003年1月至2006年11月间收治的460例患者，随访至2011年11月，采用双螺旋检测技术对GSTP1 Ile105Val、XRCC1 Arg194Trp、XRCC1 Arg399Gln、XRCC3 Thr241Met进行基因分型。聚合酶链反应与面对两对引物方法。结果：GSTP Val/Val 患者的生存时间较短，死亡风险比 IIe/IIe 基因型患者高 1.89 倍。对于 XRCC1 Arg194Trp，与 Arg/Arg 相比，变异基因型 Trp/Trp 与 NSCLC 死亡风险降低显着相关。携带 XRCC1 399Gln/Gln 基因型的个体生存时间更长，死于非小细胞肺癌的风险更低。结论：本研究表明，GSTP1 Ile105Val、XRCC1 Arg194Trp 和 XRCC1Arg399Gln 基因在改变中国人群 NSCLC 患者铂类化疗效果中发挥作用。我们的研究结果为 NSCLC 病例个体化治疗的治疗决策提供了信息。
Aim: Individual differences in chemosensitivity and clinical outcome in non-small cell lung cancer (NSCLC) patients treatment with platinum-based chemotherapy may be due to genetic factors. Our study aimed to investigate the prognostic role of GSTP1, XRCC1 and XRCC3 in NSCLC patients treated with chemotherapy. Methods: A total of 460 cases were consecutively selected from The Affiliated Hospital of Nantong University between Jan. 2003 to Nov. 2006, and all were followed-up until Nov. 2011. Genotyping of GSTP1 Ile105Val, XRCC1 Arg194Trp, XRCC1 Arg399Gln and XRCC3 Thr241Met was conducted by duplex polymerase-chain-reaction with confronting-two-pair primer methods. Results: Patients with GSTP Val/Val exhibited a shorter survival time, and had a 1.89 fold greater risk of death than did those with the IIe/IIe genotype. For XRCC1 Arg194Trp, the variant genotype Trp/Trp was significantly associated with a decreased risk of death from NSCLC when compared with the Arg/Arg. Individuals carrying XRCC1 399Gln/Gln genotype had a longer survival time, with a lowered risk of death from NSCLC. Conclusion: This study indicated that GSTP1 Ile105Val, XRCC1 Arg194Trp and XRCC1Arg399Gln genes have a role in modifying the effect of platinum-based chemotherapy for NSCLC patients in a Chinese population. Our findings provide information for therapeutic decisions for individualized therapy in NSCLC cases.